Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

HeartShare: Kombination af Omics, Deep Phenotyping og Electronic Health Records for hjertesvigt undertyper og behandlingsmål

24. september 2026 opdateret af: Sanjiv Shah, Northwestern University

HeartShare Deep Phenotyping Study

HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.

Studieoversigt

Status

Rekruttering

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

1000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • Sacramento, California, Forenede Stater, 95817
        • Rekruttering
        • University of California Davis
        • Kontakt:
          • Maiya Her
          • Telefonnummer: 916-734-0230
        • Ledende efterforsker:
          • Nipavan Chiamvimonvat, MD
        • Underforsker:
          • Javier Lopez, MD
        • Underforsker:
          • Martin Cadeiras, MD
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Northwestern University
        • Kontakt:
        • Ledende efterforsker:
          • Sadiya Khan, MD
        • Ledende efterforsker:
          • Laura Rasmussen-Torvik, PhD, MPH
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Ikke rekrutterer endnu
        • Mass General Brigham
        • Ledende efterforsker:
          • Greg Lewis, MD
        • Kontakt:
        • Underforsker:
          • Akshay Desai, MD, MPH
        • Underforsker:
          • Michael Givertz, MD
        • Underforsker:
          • Scott Solomon, MD
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic
        • Ledende efterforsker:
          • Barry Borlaug, MD
        • Underforsker:
          • Margaret Redfield, MD
        • Kontakt:
    • North Carolina
      • Winston-Salem, North Carolina, Forenede Stater, 27157
        • Ikke rekrutterer endnu
        • Wake Forest University
        • Kontakt:
          • Ben Nelson
          • Telefonnummer: 336-716-6789
        • Ledende efterforsker:
          • Dalane Kitzman, MD
        • Underforsker:
          • Alain Bertoni, MD, MPH
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • University of Pennsylvania
        • Kontakt:
          • Tiffany Sharkoski
          • Telefonnummer: 215-615-2354
        • Ledende efterforsker:
          • Julio Chirinos, MD, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

30 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adults over 30 years of age.

Beskrivelse

Inclusion Criteria:

HF Inclusion Criteria (HeartShare Registry)

  1. Age ≥30 years.
  2. Prior diagnosis of HF in the EHR (any left ventricular ejection fraction).

Non-HF Group Inclusion Criteria (HeartShare Registry)

  1. Age ≥30 years.
  2. No known prior diagnosis of HF or use of loop diuretics.
  3. No known prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml, if prior laboratory tests are available in the EHR.

HFpEF Inclusion Criteria (HeartShare Deep Phenotyping Cohort)

  1. Age ≥30 years.

  2. Left ventricular ejection fraction ≥50% measured by echocardiography.

  3. Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:

    1. Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
    2. Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).
    3. Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise).
    4. Elevated H2FPEF score26 (≥5) or HFA-PEFF27 score (≥5).

Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort)

  1. Age ≥30 years.
  2. Left ventricular ejection fraction ≥50% measured by echocardiography.
  3. No known prior diagnosis of HF or use of diuretics for fluid management.
  4. No known prior history of BNP ≥75 pg/ml or NTproBNP ≥225 pg/ml, if prior laboratory tests are available in the EHR.
  5. BNP <75 pg/ml or NTproBNP <225 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center.

Exclusion Criteria:

Exclusion Criteria (HeartShare Registry) The following exclusion criteria apply to both HF and non-HF group participants, unless otherwise indicated.

  1. For non-HF group: any prior known left ventricular ejection fraction <50%.
  2. Prior history of solid organ transplantation.
  3. Prior history of mechanical circulatory support.
  4. Prior history of non-cardiac cirrhosis.
  5. Inability to provide written consent to the study.

Exclusion Criteria (HeartShare Deep Phenotyping Cohort) The following exclusion criteria apply to both HFpEF and non-HFpEF group participants, unless otherwise indicated.

  1. Life expectancy estimated to be < 1 year.

  2. Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension).

  3. Any prior known left ventricular ejection fraction <40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation).

  4. Clinically significant valvular heart disease defined as:

    1. Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis.
    2. Any mitral stenosis.
    3. Moderate or greater aortic regurgitation.
    4. Greater than moderate mitral regurgitation.
  5. Any planned cardiac surgery or cardiac intervention in the next 3 months.

  6. Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator.

  7. Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment.

  8. Known symptomatic epicardial coronary artery disease that is not revascularized.

  9. Any non-elective hospitalization in the preceding 2 weeks.

  10. Prior history of solid organ transplantation.

  11. Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator.

  12. Prior history of mechanical circulatory support.

  13. Prior history of non-cardiac cirrhosis.

  14. Estimated GFR <20 ml/min/1.73m2 or currently on dialysis.

  15. Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator.

  16. Inability to provide written consent to the study.

  17. Current acute decompensated heart failure.

  18. Currently pregnant.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
HFpEF

Participants with HFpEF

Non-HFpEF

Participants without HFpEF

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Antal deltagere med hjertesvigt med bevaret ejektionsfraktion (HFpEF)
Tidsramme: Op til 5 år
Op til 5 år

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Sanjiv Shah, MD, Northwestern University
  • Studiestol: Svati Shah, MD, MHS, Duke University
  • Studiestol: Javed Butler, MPH, MBA, Baylor Scott and White Health

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. marts 2023

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

15. maj 2023

Først indsendt, der opfyldte QC-kriterier

15. maj 2023

Først opslået (Faktiske)

24. maj 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • STU00217900
  • U54HL160273 (U.S. NIH-bevilling/kontrakt)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .